News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dendreon Corporation (DNDN) Announces the Centers for Medicare & Medicaid Services Will Now Cover Infusion Costs Associated with the Administration of PROVENGE



11/21/2011 8:46:42 AM

SEATTLE--(BUSINESS WIRE)--Dendreon Corporation (NASDAQ:DNDN) today announced the Centers for Medicare and Medicaid Services (CMS) updated their coverage policy to now cover the infusion costs associated with the administration of PROVENGE® (sipuleucel-T). With this decision, the coverage of PROVENGE is now consistent with all other infused biologics.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES